ALYSSA ELLIS: Open Payments
NPI 1780446278 · SCHAUMBURG, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$623 in 28 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $123 · 2025 $623
Food & beverage: $623
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 5 | $204 |
| Janssen Pharmaceuticals, Inc | 5 | $109 |
| ABBVIE INC. | 3 | $56 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $43 |
| Otsuka America Pharmaceutical, Inc. | 2 | $39 |
| Supernus Pharmaceuticals, Inc. | 2 | $36 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $32 |
| Alkermes, Inc. | 1 | $30 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $19 |
Products named: INGREZZA, SPRAVATO, VRAYLAR, REXULTI, TRINTELLIX, Qelbree, CAPLYTA, ARISTADA.
Industry payments across IL — which companies pay providers there.
